Synonyms: ONC-201 | TIC-10 | TIC10
Compound class:
Synthetic organic
Comment: ONC201 (also known as TIC10 [2]) was originally discovered as a TRAIL receptor inducer and as an orally active dual Akt/ERK inhibitor [1] It exerts potent anti-tumour effects.
Note that although [1] and [2] are published by the same research group, both articles show different isomers of the chemical structure. We show the structure from their 2016 paper, which introduces ONC201 as the first-in-class imipridone anti-cancer compound [1]. PubChem CID 336423 represents the alternative isomer as depicted in the 2013 paper [2]. ONC201 was later reported as an allosteric activator of the mitochondrial protease caseinolytic protease P (ClpP) [4]. ClpP is an oncology drug target [3]. |
|
No information available. |
Summary of Clinical Use ![]() |
ClinicalTrials.gov has 16 registered ONC201 studies (in Phases 1-2), that are evaluating the compound in a wide variety of advanced solid tumours (e.g. glioma, neuroendocrine tumours, endometrial cancer, breast cancers, colorectal cancer, non-small cell lung cancer) and in hematological cancers. Click here to link to the complete list of ONC201 studies. |